Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
Executive Summary
Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains deeply committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects
You may also be interested in...
COVID-19 Staff Shakeup: Woodcock Moves to Commissioner's Office As Marks Drops Out Of 'Warp'
CBER Director Marks will no longer have to recuse himself from COVID-19 product reviews, a move seen as resoundingly positive by former senior FDA leaders. CDER Director Woodcock will now be free to focus solely on COVID-19 and bring her unique depth of agency experience to the Trump Administration's effort to speed development of vaccines, therapeutics and diagnostics for coronavirus.
FDA’s Goodman Is Rising Star Within Agency As Obama Team Coalesces
FDA's top biologics review manager Jesse Goodman is taking on a more prominent role within the agency and HHS as FDA realigns its management in anticipation of the arrival of Commissioner-designate Margaret Hamburg and her principal deputy Joshua Sharfstein
FDA’s Goodman Is Rising Star Within Agency As Obama Team Coalesces
FDA's top biologics review manager Jesse Goodman is taking on a more prominent role within the agency and HHS as FDA realigns its management in anticipation of the arrival of Commissioner-designate Margaret Hamburg and her principal deputy Joshua Sharfstein